171 related articles for article (PubMed ID: 20563590)
1. Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
Braun T; Gürkov R; Hempel JM; Berghaus A; Krause E
Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1963-7. PubMed ID: 20563590
[TBL] [Abstract][Full Text] [Related]
2. [Botulinium toxin in ENT].
Klap P
Ann Otolaryngol Chir Cervicofac; 2006 Dec; 123(6):306-11. PubMed ID: 17202988
[No Abstract] [Full Text] [Related]
3. [Use of botulinum toxin type A in neuro-ORL].
Périé S; Lacau St Guily J
Ann Readapt Med Phys; 2003 Jul; 46(6):375-9. PubMed ID: 12928145
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A for treating voice tremor.
Adler CH; Bansberg SF; Hentz JG; Ramig LO; Buder EH; Witt K; Edwards BW; Krein-Jones K; Caviness JN
Arch Neurol; 2004 Sep; 61(9):1416-20. PubMed ID: 15364688
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
7. Management of oromandibular dystonia with botulinum A toxin: a series of cases.
Teemul TA; Patel R; Kanatas A; Carter LM
Br J Oral Maxillofac Surg; 2016 Dec; 54(10):1080-1084. PubMed ID: 27776922
[TBL] [Abstract][Full Text] [Related]
8. Laryngeal dystonia: case report and treatment with botulinum toxin.
Santos VJ; Mattioli FM; Mattioli WM; Daniel RJ; Cruz VP
Braz J Otorhinolaryngol; 2006; 72(3):425-7. PubMed ID: 17119783
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor.
Kreisler A; Bouchain B; Defebvre L; Krystkowiak P
Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31413896
[TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxin for the treatment of movement disorders.
Kopanidis P; Das C
Aust J Gen Pract; 2018 Sep; 47(9):598-601. PubMed ID: 30244558
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of botulinum toxin A in the treatment of gustatory sweating].
Küttner C; Tröger M; Dempf R; Eckardt A
Nervenarzt; 2001 Oct; 72(10):787-90. PubMed ID: 11688180
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract.
Lagos-Villaseca A; Bhatt NK; Abdolhosseini P; Quinonez L; Paoletti MF; Gochman G; Johns MM; Rosen CA; Kao TC; Meyer TK
JAMA Otolaryngol Head Neck Surg; 2023 Jul; 149(7):615-620. PubMed ID: 37227721
[TBL] [Abstract][Full Text] [Related]
13. The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A.
Tugnoli V; Marchese Ragona R; Eleopra R; Quatrale R; Capone JG; Pastore A; Montecucco C; De Grandis D
Clin Auton Res; 2002 Jun; 12(3):174-8. PubMed ID: 12269549
[TBL] [Abstract][Full Text] [Related]
14. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
15. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue.
Nastasi L; Mostile G; Nicoletti A; Zappia M; Reggio E; Catania S
J Neurol; 2016 Sep; 263(9):1702-8. PubMed ID: 27278063
[TBL] [Abstract][Full Text] [Related]
16. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.
Bhattacharyya N; Tarsy D
Arch Otolaryngol Head Neck Surg; 2001 Apr; 127(4):389-92. PubMed ID: 11296046
[TBL] [Abstract][Full Text] [Related]
17. Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale.
Yoshida K
Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287925
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic and therapeutic difficulties in laryngeal dystonia].
Niebudek-Bogusz E; Modzelewska-Radwan B; Pietruszewska W; Zielińska M; Gryczyński M
Otolaryngol Pol; 2003; 57(5):739-45. PubMed ID: 14994622
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin A for treatment of sialorrhea in children: an effective, minimally invasive approach.
Khan WU; Campisi P; Nadarajah S; Shakur YA; Khan N; Semenuk D; McCann C; Roske L; McConney-Ellis S; Joseph M; Parra D; Amaral J; John P; Temple M; Connolly B
Arch Otolaryngol Head Neck Surg; 2011 Apr; 137(4):339-44. PubMed ID: 21242533
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
